statistiche ricercatore

Continente	#
EU - Europa	342
NA - Nord America	282
AS - Asia	112
SA - Sud America	87
AF - Africa	4
Continente sconosciuto - Info sul continente non disponibili	2
Totale	829

Nazione	#
US - Stati Uniti d'America	274
IE - Irlanda	79
BR - Brasile	78
IT - Italia	76
SE - Svezia	70
SG - Singapore	42
DE - Germania	32
HK - Hong Kong	27
PL - Polonia	21
CN - Cina	15
FI - Finlandia	12
AT - Austria	11
BE - Belgio	8
IN - India	7
GB - Regno Unito	5
CA - Canada	3
CZ - Repubblica Ceca	3
ES - Italia	3
FR - Francia	3
LT - Lituania	3
MX - Messico	3
VE - Venezuela	3
BD - Bangladesh	2
BY - Bielorussia	2
DO - Repubblica Dominicana	2
HU - Ungheria	2
ID - Indonesia	2
IQ - Iraq	2
IR - Iran	2
MA - Marocco	2
NL - Olanda	2
PE - Perù	2
PT - Portogallo	2
TR - Turchia	2
UA - Ucraina	2
VN - Vietnam	2
AE - Emirati Arabi Uniti	1
BG - Bulgaria	1
BO - Bolivia	1
CH - Svizzera	1
CO - Colombia	1
EC - Ecuador	1
EE - Estonia	1
EG - Egitto	1
EU - Europa	1
GE - Georgia	1
GR - Grecia	1
JP - Giappone	1
KZ - Kazakistan	1
MK - Macedonia	1
PH - Filippine	1
PK - Pakistan	1
PY - Paraguay	1
RU - Federazione Russa	1
SA - Arabia Saudita	1
TH - Thailandia	1
TN - Tunisia	1
UZ - Uzbekistan	1
XK - ???statistics.table.value.countryCode.XK???	1
Totale	829

Nome	#
PRRT Retreatments: Renal Function Evaluation	114
Peptide Receptor Radionuclide Therapy and Somatostatin 'cold' Analogues Therapy in the Treatment of GEP-NET Patients: Our Center’ Experience	108
Effectiveness, safety and haematological toxicity of 223Ra-Cl2: a single centre experience	97
A Single Centre Experience with 223-Radium-Dichloride ((RaCl2)-Ra-223) Therapy	91
Early preablation rhTSH-stimulated thyroglobulin predicts outcome of differentiated thyroid cancer (DTC) patients	88
BRAFV600Emutation is associated with increased prevalence of contralateral lymph-node metastases in low and low-to-intermediate risk papillary thyroid cancer	82
Prognostic Validity of Dual Tracer PET/CT In The PRRT Enrollment of GEP-NET Patients	76
BRAF and RAS mutations in differentiated thyroid cancer of patients with low-risk to intermediate-risk treated with radioiodine therapy	66
PSMA and Choline PET for the Assessment of Response to Therapy and Survival Outcomes in Prostate Cancer Patients: A Systematic Review from the Literature	59
Artificial Intelligence Applications on Restaging [18F]FDG PET/CT in Metastatic Colorectal Cancer: A Preliminary Report of Morpho-Functional Radiomics Classification for Prediction of Disease Outcome	55
Head-to-Head Comparison of FDG and Radiolabeled FAPI PET: A Systematic Review of the Literature	26
Totale	862

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2020/2021	71	11	2	17	2	8	4	4	6	5	4	5	3
2021/2022	92	2	4	2	8	4	3	1	3	2	9	9	45
2022/2023	280	23	37	14	22	25	35	7	19	90	3	5	0
2023/2024	60	5	4	6	3	6	18	1	0	0	5	4	8
2024/2025	333	8	10	10	12	22	11	21	64	69	22	43	41
2025/2026	12	12	0	0	0	0	0	0	0	0	0	0	0
Totale													862